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Abstract44 
45 
This guideline describes the approach and expertise needed for the genetic evaluation of 46 
cardiomyopathy. First published in 2009 by the Heart Failure Society of America (HFSA), this 47 
guidance has now been updated in collaboration with the American College of Medical Genetics 48 
and Genomics (ACMG). The writing group, composed of cardiologists and genetics 49 
professionals with expertise in adult and pediatric cardiomyopathy, reflects the emergence and 50 
increased clinical activity devoted to cardiovascular genetic medicine. The genetic evaluation of 51 
cardiomyopathy is a rapidly emerging key clinical priority, as high throughput sequencing is now 52 
feasible for clinical testing, and conventional interventions can improve survival, reduce 53 
morbidity, and enhance quality of life. Moreover, specific interventions may be guided by genetic 54 
analysis. A systematic approach is recommended: always a comprehensive family history; an 55 
expert phenotypic evaluation of the proband and at-risk family members to confirm a diagnosis 56 
and guide genetic test selection and interpretation; referral to expert centers as needed; genetic 57 
testing, with pre- and post-test genetic counseling; and specific guidance as indicated for drug 58 
and device therapies. The evaluation of infants and children demands special expertise. The 59 
approach to manage secondary and incidental sequence findings as recommended by the 60 
ACMG is provided. 61 
62 
63 
Key Words: cardiomyopathy; genetics; genetic analysis; practice guideline; secondary 64 
findings.65 
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Introduction  66 
Continued rapid progress has been made in understanding the genetic basis of 67 
cardiomyopathy. This work, which describes the content, approach and expertise needed for a 68 
cardiomyopathy genetic evaluation, was first developed in a guideline statement in 2008 and 69 
published in 2009 for the Heart Failure Society of America (HFSA).1 This has now been updated 70 
by a writing group organized with the American College of Medical Genetics and Genomics 71 
(ACMG) and the HFSA to serve as a practice resource (ACMG) and as a revised guideline 72 
statement (HFSA).  73 
This collaboration of cardiovascular and genetics professionals mirrors a recent 74 
proliferation of specialized cardiovascular genetics clinics.2 Most commonly cardiologists, adult 75 
or pediatric, with special interest or training in cardiovascular genetics, team up with genetics 76 
professionals, usually board-eligible or board-certified genetic counselors and/or clinical 77 
geneticists, ideally with cardiovascular expertise, to provide state-of-the-art genetics services to 78 
the many patients and families with cardiomyopathy. This growth has been triggered by 79 
improvements in technology for clinical genetic testing, resulting in the availability of large 80 
clinical genetic testing panels, where numerous genes of interest can be sequenced quickly, 81 
efficiently and accurately using continually developing massively parallel DNA sequencing 82 
technologies. This growth also recognizes the critical importance of integrated expert 83 
phenotypic information with final clinical recommendations in light of burgeoning sequence 84 
information.3  85 
This collaboration also speaks to the recent prominence of cardiovascular genetics and 86 
genomics brought about by the emergence of clinical exome sequencing and the ACMG 87 
recommendation, first in 20134 and updated in 2016,5 to return relevant and actionable 88 
secondary findings. Of the 59 medically actionable genes cited in 2016, 30 (51%) had 89 
cardiovascular phenotypes, and 16 (27%) were genes that included cardiomyopathy 90 
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phenotypes. By request from the ACMG, we also provide guidance for secondary findings 91 
derived from cardiomyopathy genes. 92 
The rationale for the inclusion of cardiomyopathy genes in the ACMG secondary findings 93 
list, and the basis for the clinical screening, counseling and molecular recommendations 94 
contained herein, are because the cardiomyopathies are medically actionable: well established 95 
treatments or interventions are available to improve survival, reduce morbidity, and enhance 96 
quality of life.6, 7 Cardiomyopathies may present late in their course with advanced disease, 97 
which includes heart failure, heart block and/or life-threatening arrhythmias including sudden 98 
cardiac death, and thromboembolic events, including stroke from atrial arrhythmias or 99 
ventricular thrombus. Thus, the rationale to identify genetic risk is compelling, so that those 100 
found to be at-risk can undergo interval screening to detect the earliest manifestations of the 101 
cardiomyopathy phenotype. The first evidence of a phenotype then permits earlier 102 
interventions,7 including lifestyle modifications, drugs to slow or halt disease progression or to 103 
prevent thromboembolism, and procedures, drugs or devices to reduce the risk of sudden 104 
cardiac death.6 Identification of at-risk individuals, whether affected but asymptomatic or those 105 
clinically unaffected may also have implications for genetic counseling and reproductive 106 
decision-making.  107 
Cardiovascular physicians are expert at assessing the nuances of cardiomyopathy 108 
phenotypes or sub-phenotypes, an essential contribution to cardiovascular genetics care. As in 109 
2009,1 our current approach continues to be stratified by cardiomyopathy phenotype, as clinical 110 
and genetic data collection, analysis and decision making for the cardiomyopathies remain 111 
anchored by phenotypic categories. 112 
The Family as the Unit of Care 113 
A critical transition for cardiovascular practitioners who wish to more fully actualize 114 
cardiovascular genetic medicine is to adopt the family as the unit of care, a concept inherently 115 
understood by genetics professionals. For cardiovascular providers, moving the care paradigm 116 
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beyond the patient (proband), who often presents with a fully developed phenotype and at times 117 
with advanced life-threatening disease, to at-risk relatives is mandatory to fulfill the promises of 118 
precision medicine. Moreover, collaboration with and care for the family unit is an essential 119 
component of the genetic evaluation. This includes establishing a genetic etiology for the 120 
proband and affected family members, the clinical evaluation of at-risk family members, 121 
cascade genetic testing of family members as indicated, and genetic counseling at all steps. All 122 
of this will not only augment the evidence of variant pathogenicity but also will provide insight 123 
into penetrance, age of onset, pleiotropy and disease expression. 124 
Ideally family-based cardiovascular genetic medicine also means developing integrated 125 
teams with pediatric and adult training and expertise that are able to provide coordinated care 126 
across all age groups. Identification of disease and pathogenic variants in an adult parent 127 
facilitates testing and potential treatment of pediatric-aged children. Conversely, if the index 128 
case is a child, the testing and treatment of adult-aged relatives may also be needed. Thus, we 129 
recognize the critical need to address accessible delivery of care of the family across all ages. 130 
This also includes managing insurance coverage for the evaluation of asymptomatic relatives 131 
based on their family history. 132 
Genetic cardiomyopathy has substantial complexity, as shown by overlap in phenotype 133 
as well as an overlap of genes.8 Despite this complex interplay of genes, variants and 134 
phenotypes, current knowledge when combined with expert phenotyping and the sensitivity and 135 
specificity of current genetic testing, is sufficient to effectively conduct genetic cardiomyopathy 136 
evaluations. We caution, however, that variant interpretation must be thoughtful, rigorous and 137 
leverage the most up-to-date approaches, as not all variants identified by genetic testing will be 138 
clinically significant or disease-causing. Key resources include use of the most recent 139 
ACMG/AMP guidance,5, 9 now being augmented by ClinGen, a National Human Genome 140 
Research Institute-sponsored initiative to curate genes and variants and place them into 141 
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ClinVar, a publically accessible database,10, 11 and other large publicly accessible reference 142 
databases. 143 
Types of Cardiomyopathy 144 
The genetic basis of hypertrophic cardiomyopathy (HCM) is well established, largely a 145 
disease caused by mutations in genes encoding sarcomeric proteins. That familial dilated 146 
cardiomyopathy (DCM) has a genetic basis is also well accepted. By DCM, we clarify that the 147 
DCM term herein is used in place of the more technical attribution “idiopathic dilated 148 
cardiomyopathy,” where the other common and easily clinically detected causes of systolic 149 
dysfunction such as coronary artery disease, primary valvular or congenital heart disease, or 150 
prior exposure to cancer chemotherapy or other injurious drugs, have been excluded. However, 151 
the preponderance of DCM occurs without apparent familial disease, and whether non-familial 152 
DCM is principally a genetic condition remains uncertain.8, 12, 13 The much greater numbers of 153 
genes and the diversity of variants identified (allelic and locus heterogeneity) with DCM is more 154 
extensive relative to the other cardiomyopathies,8, 12, 14, 15 making genetic testing inherently more 155 
challenging. Arrhythmogenic right ventricular cardiomyopathy (ARVC), which is much less 156 
common than HCM or DCM, also has a well-established genetic basis associated with 157 
mutations in genes that encoded desmosomal elements. Restrictive cardiomyopathy (RCM), 158 
although quite rare, also shares in part a genetic basis with HCM. 159 
In contrast to HCM, DCM, RCM and ARVC, the left ventricular non-compaction (LVNC) 160 
phenotype remains enigmatic and without consensus as to whether it should be considered a 161 
primary cardiomyopathy,13 a variant morphologic trait16 or something else.17, 18 We favor 162 
describing it as a phenotype because an increasing body of population-derived high-quality 163 
imaging evidence, not available when LVNC was deemed a primary cardiomyopathy,13 now 164 
shows that increased ratios of non-compacted (trabeculated) to compacted (non-trabeculated) 165 
myocardium may be present in 2-10% or more of the population depending on the definition and 166 
test sensitivity.16, 19, 20 Further, studies in highly trained athletes 21, 22 and pregnancy,23 suggest 167 
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LVNC may progress and regress, akin to ventricular remodeling and reverse remodeling. 168 
Therefore, LVNC has been included and referred to as a non-compaction phenotype rather than 169 
a unique form of cardiomyopathy. Additional background is provided in the online supplement.170 
171 
Approaches to Review and Publication by the ACMG and HFSA172 
The writing group was established conjointly with the ACMG and HFSA between 2013 173 
and 2015. The approaches to creating, curating and approving practice guidelines or practice 174 
resources for the HFSA and ACMG, respectively, have been outlined in each publication. The 175 
material covered in this and the companion document24 are congruent with one another. 176 
Differences in scope, including supplemental materials, are denoted and cross-referenced.  177 
The writing group was comprised of a panel of experts, board certified cardiologists and 178 
genetics professionals with experience and expertise in genetic cardiomyopathies 179 
(Supplemental Table XX), with a goal to revise a prior HFSA publication in a conjoint effort with 180 
a new document for the ACMG. Each author was screened for relevant conflicts of interest and 181 
all conflicts shown were considered non-substantial to influence the document. Dr. Vatta was 182 
included in the writing group prior to his employment with a for-profit genetic testing company; 183 
following his employment potential conflicts of interest regarding genetic testing indications were 184 
managed by his recusal from pertinent discussions.  185 
186 
Use of Medical Evidence in this Guideline 187 
We address two questions here. The first question is that of clinical validity: “Does the 188 
evaluation or test correlate with the outcome of interest?”25 Since randomized clinical trials 189 
evaluating the clinical accuracy of diagnosis with or without a genetic evaluation or genetic 190 
testing are not generally feasible, as in the prior guideline1 we have used a different format for 191 
level of evidence. By genetic evaluation we mean a systematic approach that includes a 192 
comprehensive family history, phenotypic evaluation of the proband and at-risk family members, 193 
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genetic counseling, genetic testing, if indicated, with pre- and post-test genetic counseling, and 194 
guidance as indicated for specific drug and/or device, or other specific therapeutic interventions. 195 
By genetic testing we mean DNA sequencing or other DNA testing modalities to identify DNA 196 
variants relevant for the phenotype of interest. Level A: Genetic evaluation and testing has a 197 
high correlation with the cardiomyopathic disease of interest in studies with a moderate or large 198 
sample size; Level B: Genetic evaluation and testing has a high correlation with the 199 
cardiomyopathic disease of interest in smaller or single center studies; and Level C: Genetic 200 
evaluation and testing correlates with the cardiomyopathic disease of interest in case reports. 201 
All levels were assigned based upon literature review and full consensus of the writing group. 202 
The second question is one of clinical effectiveness: “Does performing a genetic203 
evaluation or test result in improved patient outcomes?” This question depends also on the 204 
multiple treatment options that follow from a firm genetic and phenotypic diagnosis in 205 
cardiomyopathy, as well as the perceived clinical utility, which in this context is the benefit of 206 
those who receive a genetic evaluation or test. Again, randomized studies to address this 207 
question controlling for genetic diagnosis are not feasible. Moreover, consensus on how to 208 
appropriately measure the impact of genetic evaluation and testing on personal utility of patients 209 
is still developing,26 while the impact of genetic evaluation and testing on societal utility is a 210 
broader question beyond our current scope. Therefore, while acknowledging these constraints, 211 
we have interpreted the level of evidence within the existing HFSA framework,27 and have 212 
based the strength of recommendations on this level, as well as on our current knowledge of 213 
clinical effectiveness from the totality of information currently available. 214 
While we recognize that essentially no randomized controlled clinical trials have been 215 
conducted to support most of the recommendations herein, this also provides an opportunity to 216 
press our constituencies to design and conduct innovative and rigorous research studies to 217 
achieve a substantive evidentiary basis for these guidelines. While the present guidance may be 218 
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considered “expert” it is well known that well designed and rigorously performed clinical studies 219 
have routinely shown that “conventional wisdom” may be simply wrong. 220 
221 
Guideline 1.  Obtaining a family history of at least three generations, including the 222 
creation of a pedigree, is recommended for all patients with a primary 223 
cardiomyopathy. 224 
Cardiomyopathy Phenotype  Level of Evidence 225 
Hypertrophic cardiomyopathy (HCM)  A 226 
Dilated cardiomyopathy (DCM) A 227 
Arrhythmogenic right ventricular cardiomyopathy (ARVC) A 228 
Restrictive cardiomyopathy (RCM) A 229 
Cardiomyopathies with extra-cardiac manifestations A 230 
Left ventricular non-compaction (LVNC)  see background 231 
232 
Key Points: A genetics professional is skilled at obtaining a reliable family history and 233 
identifying those at risk, which is critically important once genetic results have been obtained. 234 
Specific questions should be focused to elicit possible affected relatives that may not be 235 
identified in a general family history. Primary clinical data should be reviewed, whenever 236 
possible, and may require collection of relatives’ records or post mortem reports. These latter 237 
may include relevant prenatal (including fetal loss), infant, pediatric, or adult records.238 
239 
Guideline 1 - Background.240 
The family history, a key component of any medical and genetic evaluation, is 241 
particularly relevant for the cardiomyopathies. The goals of a family history are to ascertain if the 242 
cardiomyopathy is inherited, establish the inheritance pattern, identify at-risk family members, 243 
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and provide information on disease characteristics within the family (e.g., age of onset, severity, 244 
phenotypic variability within the pedigree, and treatment response). Reduced penetrance, 245 
defined as individuals possessing a pathogenic variant but not manifesting any evidence of 246 
disease, and variable expressivity is not uncommon in cardiomyopathy. For this reason a family 247 
history of at least three generations is needed to determine the pattern of inheritance (dominant, 248 
recessive, X-linked, mitochondrial).28 Family history of more distantly affected relatives may be 249 
informative regarding the pattern of disease within the family, through increased numbers of 250 
affected individuals in the data set. 251 
The writing group strongly recommends placing the family history into a graphical 252 
pedigree format to enhance genetic competency for data interpretation, managing family-based 253 
clinical screening, determining the mode of inheritance, facilitating the assessment of relatives 254 
at risk, and for family counseling.2 255 
Most cardiomyopathies presenting in adulthood are inherited in an autosomal dominant 256 
manner. Cardiomyopathy presenting in childhood is also frequently inherited as an autosomal 257 
dominant condition, but is more likely to have autosomal recessive, X-linked or mitochondrial 258 
inheritance than in adults. De novo variants may be found in children or adults. In children, de259 
novo variants are most commonly identified for autosomal dominant and X-linked syndromic 260 
cardiomyopathies. A child may be the first individual in a family to come to attention with a 261 
primary HCM, DCM, or ARVC, and have a negative family history.  Studies have shown de novo 262 
events in up to 1/3 of cases with a negative family history, however cardiomyopathy may also 263 
occur due to inheritance from an affected but asymptomatic parent unaware they have 264 
disease.29, 30265 
Assumptions regarding paternal or maternal transmission should be avoided, as bilineal 266 
inheritance of autosomal dominant cardiomyopathy (transmission of disease from both mother 267 
and father) can occur and may incur more severe and earlier onset disease. Compound or 268 
digenic heterozygous variants classified in earlier studies have been shown in up to 5% of HCM 269 
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and up to 20% in ARVC patients,31-33 although a re-evaluation of the previously published HCM 270 
double variants applying the 2015 ACMG approach9 indicated double pathogenic or likely 271 
pathogenic double variants were much less common.34 Reliable data for DCM are not yet 272 
available but also may be prevalent.35 If the inheritance pattern can be established, accurate 273 
risk assessment of relatives can be provided. While some digenic conditions have been clearly 274 
established,36 well-designed rigorous studies investigating di- or multigenic inheritance for the 275 
cardiomyopathies are needed. 276 
A family history provided by patients is frequently inadequate and may miss familial 277 
cardiomyopathy.37 Details from patients regarding heart disease in their family may be lacking, 278 
and vague terms such as “heart attack” or “stroke” may be used for any sudden or unexplained 279 
death. Ideally family history should be obtained from the most informed family member. Similar 280 
to medical history, family history is dynamic and should be updated at regular intervals. Specific, 281 
focused questions should be asked to ensure affected relatives are identified. Key elements 282 
include: 1) cardiovascular symptoms (e.g., shortness of breath, paroxysmal nocturnal dyspnea, 283 
or dyspnea on exertion), or symptoms suggestive of arrhythmia, including palpitations, 284 
presyncope or syncope with or without exercise; 2) cardiovascular diagnoses such as 285 
cardiomyopathy, heart failure or valve disease, or prior procedures including cardiac 286 
catheterization, arrhythmia ablation, cardioversions, heart surgery, heart transplant, or use of 287 
pacemakers or implantable cardioverter defibrillators (ICDs); all of these should include age at 288 
time of symptom onset, procedures, or death; 3) sudden death, particularly under age 40, with 289 
special attention to single vehicle accidents, drowning, or sudden infant death; 4) previous 290 
genetic testing; 5) specific details on deaths attributed to “heart attack”; and 6) features of 291 
syndromes, especially any features suggesting skeletal muscle disease. Also, if applicable; e.g. 292 
short stature and learning problems suggesting Noonan, acroparesthesias and renal failure 293 
consistent with Fabry or skeletal myopathy. 294 
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A critical component to validate family history often includes obtaining medical records 295 
and/or post mortem reports. Obtaining a family history and related activities outlined are time 296 
and effort intensive. Alternatively, focused family history interviews can be accomplished by 297 
trained allied health professionals. Practitioners may choose to refer patients with 298 
cardiomyopathy to centers expert in genetic cardiomyopathies, to obtain detailed family 299 
histories, provide genetic counseling and genetic testing, compile clinical and genetic 300 
databases, and provide opportunities to participate in research studies that are essential for 301 
progress in the field. 302 
As noted above (Introduction, Supplementary Material), left ventricular noncompaction 303 
(LVNC) observed in conjunction with HCM, DCM, ARVC or RCM follows guidelines for that of 304 
the associated subtype of cardiomyopathy. If isolated noncompaction is identified 305 
serendipitously in an individual who is otherwise normal (asymptomatic with a normal ECG and 306 
normal ventricular size and function), it is always reasonable to obtain a family history to ensure 307 
there is no evidence of cardiomyopathy in the family, although formal population-based family 308 
studies of such individuals have not been published. Please see additional discussion at 309 
Guidelines 2 and 4. 310 
Guideline 2. Clinical (phenotypic) screening for cardiomyopathy in at-risk first-311 
degree relatives is recommended.  312 
Cardiomyopathy Phenotype Level of Evidence 313 
Hypertrophic cardiomyopathy (HCM) A 314 
Dilated cardiomyopathy (DCM) A 315 
Arrhythmogenic right ventricular cardiomyopathy (ARVC) A 316 
Restrictive cardiomyopathy (RCM) A 317 
Cardiomyopathies, overlapping, or extra cardiac A 318 
Left ventricular noncompaction (LVNC) see background 319 
Page 13 of 72
14 
320 
Key Points: Cardiomyopathies are frequently clinically silent for extended periods of time. 321 
Thus, first-degree relatives may be reportedly unaffected, and cardiomyopathy can only be 322 
detected by clinical testing (denoted hereafter as “phenotype screening”). Relatives who323 
complete phenotype screening with no evidence of disease are denoted as “clinically324 
unaffected.” Relatives who are asymptomatic but have not completed phenotype screening are 325 
denoted hereafter as “reportedly clinically unaffected.” Development of disease is age 326 
dependent, thus assessments of at-risk relatives may require repeated phenotype screening. 327 
328 
a. Baseline phenotype screening is recommended for all at-risk first-degree329 
relatives, including those who have tested negative for a known familial variant. (Level of 330 
Evidence = A)331 
The rationale for baseline phenotype screening for at risk family members is that, as 332 
noted above, cardiomyopathy is commonly clinically silent and can only be detected by clinical 333 
screening. The rationale for phenotyping family members who test negative for a familial variant 334 
known to be actionable (i.e., pathogenic or likely pathogenic) is because in some cases non-335 
segregation (an individual with the cardiomyopathy phenotype who tests negative for a 336 
pathogenic or likely pathogenic variant in the pedigree) will be unmasked, thus prompting the 337 
need for expanded genetic evaluation. We also note that determining whether a variant of 338 
uncertain significance (VUS) identified in the proband segregates with cardiomyopathy in a 339 
family can only be accomplished with up-to-date clinical phenotype information in all at-risk 340 
members of the pedigree. Furthermore, many variants continue to be novel for the 341 
cardiomyopathies (the exception being for some variants in MYH7 and MYBPC3 where larger 342 
numbers of pathogenic variants have been identified in HCM38) and thus if only observed in the 343 
proband will likely be assigned as a VUS, whereas knowledge of other affected family members 344 
who also carry a variant initially assigned as a VUS may enable its reclassification to likely 345 
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pathogenic or pathogenic, which can then be used for predictive testing. For these reasons we 346 
advocate that baseline clinical phenotype screening be conducted for all at-risk family members 347 
in conjunction with initial cascade genetic testing of a family’s disease-causing variant or 348 
variants. Please see Guideline 3 for comments specific to children.  349 
350 
b. Serial phenotype screening for cardiomyopathy is recommended in clinically351 
unaffected, at-risk relatives who are known to carry one or more disease-causing 352 
variants. (Level of Evidence = A) 353 
Serial screening means, following a baseline-screening event, regular and repeated 354 
phenotype screening events are then conducted over a period of years.  355 
356 
c. Serial phenotypic screening for the emergence of cardiomyopathy is357 
recommended for clinically unaffected at-risk first-degree relatives whose genetic status 358 
is unknown. (Level of Evidence = A)359 
An unknown genetic status can occur when an at-risk individual has not yet been tested 360 
for a previously detected disease-causing variant in the family, or if no pathogenic or likely 361 
pathogenic variant has been identified in the proband. It can also occur if a VUS has been 362 
identified in the proband and the family-based or other data are insufficient to allow 363 
reclassification as a likely pathogenic variant.  364 
365 
d. Serial screening of clinically unaffected relatives who have negative genetic366 
testing for a pathogenic variant is not recommended. (Level of Evidence = A) 367 
This recommendation is based upon the certainty that the variant identified in a family is 368 
indeed pathogenic and is discussed below at Guideline 4. However, relatives should be 369 
counseled to present for evaluation if they develop signs or symptoms suggestive of disease. 370 
371 
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e. Clinical phenotype screening is recommended. (Level of Evidence = A) 372 
Clinical phenotype screening (Table 1) includes: 373 
 Medical history, with special attention to heart failure symptoms, arrhythmias,374 
presyncope or syncope, and thromboembolism.375 
 Physical examination.376 
o Special attention should be given to cardiac and neuromuscular systems.377 
o Examination is indicated of the integumentary system when ARVC is378 
suspected.379 
 Electrocardiogram.380 
 Cardiovascular imaging. This includes, minimally, a two-dimensional trans-thoracic381 
echocardiogram (2D-TTE) for all cardiomyopathies, augmented with tissue Doppler382 
interrogation, if available, for HCM. Cardiac MRI is rapidly emerging as a definitive383 
imaging modality; it should be used if echocardiographic imaging is inadequate or384 
equivocal. Additional studies may be considered based on the type of385 
cardiomyopathy and/or if symptoms are present.386 
387 
f. Suggested Clinical Screening Intervals for At-Risk Family Members.388 
Clinical screening intervals are suggested (Table 2). 389 
390 
Guideline 2 - Background.391 
Cardiomyopathies span all ages – from prenatal to the elderly. The approach to clinical 392 
phenotype screening of family members always relies on cardiac electrical, structural and 393 
functional evaluations, with age- or phenotype-specific additions as needed. An ECG and an 394 
echocardiogram are usually foundational in the initial phenotype screening for all ages of at-risk 395 
pediatric and adult first-degree relatives. 396 
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Integration of the considerations given above, most importantly the type of 397 
cardiomyopathy, should also be taken into account in screening of children. While children, 398 
even neonates, do manifest cardiomyopathy, most disease is adolescent- or adult-onset. Hence 399 
these recommendations should be integrated with the type of cardiomyopathy, the age of onset 400 
of other affected members in the pedigree when such data are available, the identity of the 401 
cardiomyopathy gene, if known, and other features. Additional guidance for the evaluation of 402 
cardiomyopathy in pediatrics is covered in the next section. 403 
Adult-onset cardiomyopathies commonly show variable expressivity, a variable age of 404 
onset and reduced penetrance. Clinical screening of first-degree relatives of adults diagnosed 405 
with cardiomyopathy is indicated, regardless of whether a disease-causing variant has been 406 
identified in the index patient. In cases where first-degree relatives are all clinically unaffected, it 407 
is reasonable to initiate genetic testing in the affected patient since identification of a previously 408 
known disease-causing variant could lead to cascade testing in first-degree relatives. Because 409 
of the variable age of onset, clinical screening repeated at intervals is recommended, even if 410 
clinical genetic testing has not identified a disease-causing variant in the proband. 411 
The risk for developing HCM after 50 years of age is reduced but not eliminated39 as is 412 
that for ARVC after age 50.40 The favorable utility and role of Holter monitoring in the diagnosis 413 
of ARVC has been reviewed.40 Magnetic resonance imaging is useful for the diagnosis of ARVC 414 
in centers experienced in its use and interpretation for ARVC;41 data are not yet available to 415 
guide the frequency of its application for screening at-risk family members. 416 
As noted above (Introduction, Supplementary Material), LVNC may be observed in 417 
conjunction with other cardiomyopathy phenotypes, and if so, recommendations for that 418 
cardiomyopathy drive clinical screening recommendations. We lack data on whether, in the 419 
setting of normal ventricular size and function, the LVNC phenotype foreshadows the later 420 
development of a specific cardiomyopathy or other forms of cardiovascular disease in an 421 
extended pedigree. This is because the present literature of family-based screening has been 422 
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derived from LVNC identified at referral centers, in most cases in the setting of other 423 
cardiovascular disease.42-44 Large systematic population-based studies to identify individuals 424 
with the LVNC phenotype but otherwise with normal cardiac morphology and function, followed 425 
by studies of their family members have not been done, although limited preliminary data are 426 
available.42, 43 Because of the high prevalence of the LVNC phenotype in otherwise normal 427 
individuals in population-based studies,19, 20 the limited evidence of disease causation from the 428 
LVNC phenotype itself, and the limited individual and pedigree natural history data from 429 
population-based studies, we provide no recommendations regarding family-based phenotype 430 
screening of LVNC that is not accompanied by other cardiovascular phenotypes with known 431 
disease risks. 432 
433 
Guideline 3. Referral of patients with genetic, familial or other unexplained forms 434 
of cardiomyopathy to expert centers is recommended. 435 
436 
a. Infants and children with cardiomyopathy should be evaluated by clinicians with437 
specific expertise in the recognition and testing of syndromic and non-syndromic438 
presentations of cardiomyopathy in this age group.439 
440 
Key Points: Expert centers are those with expertise in the evaluation, diagnosis and 441 
management of genetic heart disease. Core competencies of expert centers include expertise 442 
with cardiovascular phenotypes as well as the conduct of genetic evaluations. Such centers 443 
should also have expertise in adults and/or children, dependent upon the ages of patients 444 
referred. Especially for infants and children, this includes clinicians who are able to recognize 445 
and characterize syndromes, dysmorphology, and metabolic abnormalities. Personnel at expert 446 
centers include physicians who are board-eligible or board-certified in cardiovascular disease, 447 
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working collaboratively with genetics professionals, including genetic counselors and/or clinical 448 
geneticists, ideally with cardiovascular expertise.   449 
450 
Guideline 3 - Background.451 
This recommendation is based on the marked genetic heterogeneity observed in 452 
cardiomyopathy, the increasingly complicated interpretations of human DNA variation, and the 453 
syndromic associations with some forms of cardiomyopathy. As noted below, both pre- and 454 
post-test genetic counseling should be provided by a healthcare professional who is board-455 
eligible or board-certified in genetic counseling or clinical genetics, ideally with specialty training 456 
and experience in cardiovascular genetics. Although all healthcare professionals are expected 457 
to have core competencies in genetics, most cardiovascular providers do not have specific 458 
training or certification in clinical genetics or genetic counseling.2 The 2009 HFSA practice 459 
guideline in genetic evaluation of cardiomyopathy acknowledged the challenges of obtaining a 460 
family history.1 The 2013 ACC/AHA guidelines also highlight the importance of obtaining at least 461 
a 3-generation family history in the evaluation of cardiomyopathy.6 However, the genetic 462 
evaluation of cardiomyopathy is more complex than identification of a familial pattern of disease. 463 
This includes expert phenotyping to guide test selection and rigorous interpretation of genetic 464 
testing results. Also, one recent study of genetic testing in clinical practice cited problems with 465 
incorrect or inappropriate ordering, errors in analysis, incorrect interpretations, and incorrect 466 
follow-up regarding VUSs, potentially jeopardizing patient safety.45 467 
In contrast with other subspecialty areas in cardiovascular disease, no consensus or 468 
formal definition of the requirements for expertise in cardiovascular genetics is currently 469 
available. Some training programs in Advanced Heart Failure and Transplant Cardiology or in 470 
Cardiac Electrophysiology include genetics exposure, but typically training is insufficient to 471 
achieve expertise to conduct an independent cardiovascular genetic evaluation. Similarly, 472 
training programs in Clinical Genetics typically provide exposure to diagnostic evaluation of 473 
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cardiomyopathy, but may not provide sufficient training or experience in the recognition, 474 
management and risk stratification of the heterogeneous cardiac phenotypes found in this 475 
patient population.  Clinical practice in cardiovascular genetics requires that practitioners remain 476 
up to date with the wide range of genes in which pathogenic variants cause cardiac phenotypes, 477 
including various forms of cardiomyopathy, arrhythmia, and syndromes in which these 478 
cardiovascular manifestations occur. For these reasons the ideal construct includes a close 479 
collaboration of specialists in both fields. 480 
Because of the genetic and phenotypic heterogeneity inherent among different forms of 481 
cardiomyopathy, a single healthcare provider is unlikely to be able to provide expert care alone. 482 
Often, the range of expertise required is best achieved with a team of personnel who have 483 
complementary training and experience, as a multidisciplinary approach is frequently essential 484 
for optimizing diagnosis and management.2, 46, 47 Often a board-eligible or board-certified 485 
genetics professional will work in conjunction with clinicians who are board-eligible or board-486 
certified in Cardiovascular Disease, pediatric, adult or both. One or more members of an expert 487 
team involved with evaluation of cardiomyopathies may have subspecialty certification in 488 
Advanced Heart Failure and Transplant Cardiology, and/or subspecialty certification in Cardiac 489 
Electrophysiology. The evaluation of genetic heart disease includes whole families, so expert 490 
centers ideally have teams of physicians and counselors who are experienced with providing 491 
care for both adults and children with genetic forms of heart disease. Expert centers should be 492 
able to advise patients properly about patterns of inheritance, family members who are at risk of 493 
developing genetic heart disease, and reproductive risks related to variants in genes involved 494 
with cardiomyopathies. 495 
Although referral to an expert center is recommended for genetic evaluation of patients 496 
with familial or otherwise unexplained forms of cardiomyopathy, the practicality of this 497 
recommendation varies regionally. Travel to an expert center for genetic evaluation of 498 
cardiomyopathy may not be feasible for some patients and their families. Additional options 499 
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through telephone-based genetic counseling and telemedicine-based genetic evaluation may 500 
help in part to address this shortcoming.48 501 
502 
The Evaluation of Cardiomyopathy in Children Requires Special Expertise:503 
Cardiomyopathy in children presents a unique differential diagnosis list, as compared to 504 
adults, and geneticist evaluation may be required as syndromic and metabolic causes of 505 
disease represent a higher proportion in children than in the adult population.49, 50 This is 506 
particularly relevant in patients with intellectual disability of unknown etiology. Other extra-507 
cardiac findings that should prompt further evaluation and referral include dysmorphic features, 508 
short stature, congenital anomalies, muscle weakness, or sensory deficits of unknown etiology. 509 
Age at presentation may greatly aid in refining the differential list, with a specific set of disorders 510 
more common in infancy. While there are many conditions that may cause cardiomyopathy in 511 
childhood (see Supplemental Table for examples), a few are notable for having specific, time-512 
critical treatments available, or because the identification of the cardiomyopathy in the presence 513 
of other findings may solidify the diagnosis of a specific syndrome. A number of conditions can 514 
be screened by relatively inexpensive and rapid biochemical tests, followed by genetic testing 515 
for a molecular diagnosis. 516 
Aside from neuromuscular disorders, inborn errors of metabolism, and specific 517 
syndromes noted in children, the same causes of familial HCM and DCM common in adults are 518 
also encountered throughout childhood.51 519 
Equally, syndromes with cardiomyopathy as a component may not be diagnosed until 520 
adulthood, and thus syndromic cardiomyopathies should also be part of the differential 521 
diagnosis among adults. In some cases, the dysmorphic features that form an integral part of 522 
the diagnosis in infancy and childhood may not be as prominent later in life. 523 
Infancy. Inborn errors of metabolism (IEMs) constitute an important group of conditions 524 
that may manifest early in life. While expanded newborn screening may identify potentially 525 
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affected individuals, false negatives and missed screening confirmations can occur. Not all 526 
diseases are screened in all jurisdictions, and some conditions are not currently amenable to 527 
screening. Disorders of energy metabolism in particular should be considered: these may 528 
present as either HCM or DCM, and include fatty acid oxidation defects (eg. very long-chain 529 
acyl-CoA dehydrogenase [VLCAD], carnitine palmitoyl transferase 2 [CPT2], long-chain 3-530 
hydroxyacyl-CoA dehydrogenase [LCHAD] deficiency) and mitochondrial oxidative 531 
phosphorylation disorders. If suspected, acylcarnitine profile, serum amino acids, urine organic 532 
acids, liver transaminases, serum lactate, and comprehensive metabolic profile are 533 
recommended first line studies. HCM in infancy should always invoke investigation for infantile 534 
Pompe disease (glycogen storage disease type II) by enzyme assay for acid alpha-glucosidase 535 
deficiency as early diagnosis is crucial for successful treatment by enzyme replacement 536 
therapy. Of note, HCM may also occur secondary to corticosteroid use in preterm infants with 537 
respiratory distress syndrome52, 53 or maternal diabetes54 and should resolve spontaneously. 538 
Persistence of HCM more than 4 weeks after cessation of steroids or past 6 months of age in an 539 
infant of a diabetic mother should prompt evaluation for other causes. 540 
Some syndromes with cardiomyopathy may present in infancy. Noonan syndrome or 541 
other RASopathies are the most common syndromes associated with HCM, and may have 542 
extra-cardiac manifestations of short stature and dysmorphic features that may be subtle and 543 
difficult to recognize. HCM occurs in up to 20-30% of cases, with half presenting prior to 12 544 
months of life with a more severe hypertrophy that paradoxically may improve over time.55, 56 545 
This may be biventricular, or involve predominantly the right ventricle. HCM rarely newly 546 
develops past age of 5 years.57 Molecular testing for RASopathies gene panel testing may or 547 
may not be included with sarcomeric HCM genetic testing panels. 548 
Childhood. Cardiomyopathy due to IEM may present in early or late childhood, typically 549 
in individuals previously diagnosed with a specific disorder who receive cardiac screening. 550 
Examples include the amino acid metabolism disorders methylmalonic acidemia and propionic 551 
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acidemia, glycogen storage disease type III (or very rarely type IV), and mucopolysaccharidoses 552 
(MPS).  Occasionally these conditions escape diagnosis or are misdiagnosed. 553 
Neuromuscular disorders may first manifest with DCM in childhood, and include 554 
muscular dystrophies (dystrophinopathies, laminopathies, desminopathies, 555 
sarcoglycanopathies, and other recessive and dominant limb-girdle muscular dystrophies) and 556 
Friedreich ataxia. Myotonic dystrophy, Types I and II, also present with cardiomyopathy 557 
although more commonly in adults, especially type II. Both types also have risk for conduction 558 
system disease.58 Mitochondrial disorders may also present primarily as symptomatic 559 
cardiomyopathy throughout childhood. Finally, boys with early onset cardiomyopathy should be 560 
carefully evaluated for Barth syndrome (skeletal myopathy, small size, cyclical neutropenia, 561 
delayed puberty, 3-methylglutaconic aciduria), an X-linked condition due to pathogenic variants 562 
in TAZ, which is important for mitochondrial function.59 Mitochondrial disorders may exhibit HCM 563 
(~60%) or DCM (~30%).60 564 
Selected Syndromes with Cardiomyopathy. Careful history and physical exam are 565 
essential to identify possible extra-cardiac manifestations of syndromes which may change 566 
investigation and management. It is estimated that up to 10% of children with cardiomyopathy 567 
have an underlying genetic syndrome. Over 100 different syndromes have been described with 568 
cardiomyopathy as a feature. While most are very rare, several occur with higher frequency and 569 
should be considered in the differential diagnosis (see Supplemental Table). 570 
Several syndromes present more commonly in childhood. Alström syndrome may 571 
present with transient DCM in infancy and later reoccurrence of DCM or restrictive 572 
cardiomyopathy in adolescence. Other features include visual impairment (due to cone-rod 573 
dystrophy) with nystagmus, progressive sensorineural hearing loss, obesity and diabetes due to 574 
insulin resistance. Danon disease, an X-linked condition due to pathogenic variants in LAMP2, 575 
frequently manifests in early childhood.61 It resembles infantile Pompe disease with severe HCM 576 
but less pronounced skeletal myopathy, and has additional problems of cardiac pre-excitation, 577 
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intellectual disabilities, and retinal pigmentary disease. The variability in extra-cardiac features is 578 
not well understood. Female carriers may present with either HCM or DCM, most often in the 579 
second or third decades. Severe HCM due to 5′ AMP-activated protein kinase (AMPK) 580 
deficiency encoded by PRKAG2 leading to non-lysosomal glycogen accumulation may also 581 
present in childhood, frequently with arrhythmias, heart block and Wolf-Parkinson-White.62 582 
Fabry disease, an X-linked disorder resulting from mutations in GLA, causes deficiency of 583 
alpha-galactosidase. Fabry may present as early as adolescence with LV hypertrophy. 584 
Manifestations of classic Fabry include extra-cardiac features of angiokeratomas, painful 585 
acroparesthesias, corneal opacities, reduced sweating, and end stage renal disease due to loss 586 
of enzyme activity (typically <1%). However, variants in GLA that leave some residual enzymatic 587 
function may result in cardiac variant Fabry, which usually presents at 40 years and older, in 588 
which left ventricular hypertrophy is identified with or without proteinuria and without other extra-589 
cardiac manifestations.63 Early enzyme replacement therapy, particularly for males and severely 590 
affected females of this X linked disorder, may slow progression of disease. Atypical forms of 591 
Fabry include a cardiac variant consisting of HCM, arrhythmia and conduction abnormalities 592 
without renal failure, neuropathy or skin findings and present at a later age. 593 
594 
Guideline 4. Genetic testing is recommended for patients with cardiomyopathy. 595 
596 
a. Genetic testing is recommended for the most clearly affected family member.597 
598 
b. Cascade genetic testing of at-risk family members is recommended for599 
pathogenic and likely pathogenic variants.600 
601 
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c. In addition to routine newborn screening tests, specialized evaluation of infants602 
with cardiomyopathy is recommended, and genetic testing should be considered.603 
604 
Cardiomyopathy Phenotype Level of Evidence 605 
Hypertrophic cardiomyopathy (HCM) A 606 
Dilated cardiomyopathy (DCM) A 607 
Arrhythmic right ventricular cardiomyopathy (ARVC) A 608 
Restrictive cardiomyopathy (RCM) B 609 
Cardiomyopathies associated with other A 610 
 extra-cardiac manifestations 611 
Left ventricular noncompaction (LVNC) See background 612 
613 
Key Points: Genetic testing is recommended to determine if a pathogenic variant can 614 
be identified to facilitate patient management and family screening. The identification of at risk 615 
family members is critical because the first presentation may be sudden death. Cascade genetic 616 
screening identifies asymptomatic affected family members and clinically unaffected carriers of 617 
pathogenic variants.64 Institution of therapy in asymptomatic affected individuals improves 618 
outcomes and decreases hospitalization and death due to heart failure.65, 66 Preliminary studies 619 
indicate that treatment of clinically unaffected carriers of pathogenic variants may improve 620 
outcome as well although larger studies are needed.67 Genetic testing and cascade screening 621 
for HCM have been shown to be cost-effective in Australia and the United States.68, 69 The 622 
identification of a molecular cause may also lead to critical gene-specific cardiac or extra-623 
cardiac management recommendations. For example, cardiac hypertrophy seen in LAMP2, 624 
PRKAG2, PTPN11 and RAF1 pathogenic variant carriers can represent a genocopy of 625 
hypertrophy seen with sarcomeric pathogenic variants; yet LAMP2, PRKAG2, PTPN11 and 626 
RAF1 patients have different clinical courses and management needs.70, 71 In sarcomeric 627 
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carriers, genotype status is associated with long term outcomes, including all-cause mortality.72, 628 
73 In DCM, there is evidence for prognostication value of genetic testing74-77 and management 629 
implications for specific genetic findings, such as consideration of ICD for primary prevention in 630 
carriers of LMNA pathogenic variants.78 In ARVC, ICD placement for primary prevention in 631 
asymptomatic male carriers of a malignant pathogenic variant showed significant impact on 632 
long-term clinical outcome.79 633 
Testing should ideally be initiated on the person in a family with the most definitive 634 
diagnosis and most severe manifestations. This approach will maximize the likelihood of 635 
obtaining diagnostic results and detecting whether multiple pathogenic variants may be present 636 
and contributing to variable disease expression or severity. Please see Guideline 3 for 637 
additional comments on specialized evaluation of infants and children. 638 
639 
Guideline 4 - Background 640 
Nomenclature follows the ACMG approach9 for calling variants as pathogenic (P), likely 641 
pathogenic (LP), variants of uncertain significance (VUS), likely benign and benign. The 642 
indications for genetic testing include guiding patient management and facilitating family 643 
screening and reproductive risk assessment.  644 
645 
Test Selection: Genes and Gene Panels 646 
Since the 2009 HFSA guideline,1 the number of genes known that harbor rare 647 
pathogenic variants that cause cardiomyopathy has increased, the number of clinical 648 
laboratories performing high volume cardiovascular genetic testing has expanded, and the 649 
number, type, and technologies available for gene-based sequencing have been in constant 650 
evolution. While the 2009 guideline suggested that “genetic testing should be considered,”651 
additional data on the importance of genetic testing for prognostication and management as well 652 
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as cascade screening and risk stratification of relatives support the current genetic testing 653 
recommendation. Furthermore, the cost for most large genetic panels is substantially lower than 654 
it was in 2009, with expectations for continued decline.80 Nevertheless, genetic testing is 655 
probabilistic in nature and interpretation of genetic variation will continue to be refined as 656 
additional sequencing information becomes available from both affected and unaffected 657 
individuals.  658 
The rationale for level of evidence presented in this guideline is derived largely from the 659 
660 
661 
662 
663 
664 
665 
666 
667 
668 
669 
670 
671 
672 
673 
674 
675 
676 
published sensitivity of genetic testing. These guidelines do not address molecular testing in 
prenatal, newborn screening or in-vitro fertilization settings.  
We also note ongoing challenges of variant interpretation in non-Caucasian, non-
Northern European populations, as most genetic testing, and hence repositories of known 
pathogenic variants, has previously been conducted principally in the Caucasian/Northern 
European population. The recent development of very large population databases (e.g., ExAC, 
http://exac.broadinstitute.org, or gnomAD, http://gnomad.broadinstitute.org) now provides 
limited numbers of reference alleles from non-European cohorts, which has greatly assisted 
variant interpretation. However, genetic test interpretation of variant alleles from ethnic groups 
not represented or represented in low numbers in reference datasets become extremely 
challenging, and must be approached with considerable caution.
A variety of resources are publicly available that provide additional relevant information 
(e.g., GeneReviews, http://www.ncbi.nlm.nih.gov/books/NBK1116), on individual genes (e.g., 
Online Mendelian Inheritance in Man, http://www.omim.org ), specific genetic variants and their 
population frequencies (e.g., dbSNP, http://www.ncbi.nlm.nih.gov/snp; ExAC browser, 
http://exac.broadinstitute.org; Genome aggregation database (gnomAD) 
http://gnomad.broadinstitute.org/; exome variant server, http://evs.gs.washington.edu/EVS or 
1000 Genomes, http://www.1000genomes.org), and information for the interpretation of these 
677 
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variants (e.g., ClinVar, http://www.ncbi.nlm.nih.gov/clinvar and ClinGen, 678 
http://www.clinicalgenome.org).  679 
We also note that large insertion/deletion variants (e.g., > 25 nucleotides) and other 680 
structural changes in DNA, referred to as copy number variants, in a preliminary study represent 681 
< 1% of cardiomyopathy cases,81 although structural variants have received minimal 682 
investigation in the cardiomyopathies and may have greater relevance than is currently 683 
understood. 684 
Whom to test. In order to yield the most conclusive, informative results, diagnostic 685 
genetic testing is optimally initiated on a confirmed affected individual. Furthermore, as there are 686 
sometimes multiple genetic variants contributing to disease in a single family, the testing should 687 
ideally be initiated on the person who is most likely to harbor the disease-causing variant or 688 
variants. This is frequently the individual in the family with the most severe disease and/or the 689 
earliest disease onset. This is a well-established principle in clinical genetics, as selecting the 690 
individual with the most evident disease increases the likelihood of finding a genetic cause. If 691 
the ideal person for initiation of genetic testing in a family is unavailable or unwilling to proceed, 692 
then comprehensive genetic testing should be considered for another affected family member. 693 
When to test. The timing for ordering genetic testing in a patient with cardiomyopathy 694 
has not been studied. Because results may guide management, we recommend genetic testing 695 
at the time a new cardiomyopathy diagnosis is made, but it can be conducted at any time 696 
following diagnosis. Education and counseling regarding genetic testing options are a key 697 
component of the process. For those who have had genetic testing in the past, re-testing may 698 
be appropriate if the previous testing produced negative or inconclusive results and the test’s 699 
detection rate has improved. This latter point is particularly relevant for DCM as the gene panels 700 
have rapidly expanded (e.g., inclusion of TTN15, 82, 83 and others) and are anticipated to continue 701 
expanding.  702 
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Genetic testing for the cardiomyopathies may best be viewed as continuously evolving, 703 
as new genes, and hence larger panels with greater sensitivity, continue to emerge. Although 704 
no data are available, we suggest that repeat genetic testing is reasonable if test sensitivity has 705 
increased by 5-10%. An alternative approach is to tailor retesting if particular characteristics of 706 
the patient’s phenotype are consistent with a newly identified gene. Further, the genetics 707 
provider involved in a patient’s care should periodically revisit results as variants may be 708 
reclassified over time.46, 84, 85 Such reclassification includes upgrading variants from VUS to 709 
likely pathogenic or pathogenic, as additional probands and affected family members with the 710 
phenotype of interest are found to carry the variant. Conversely, some variants, previously 711 
considered pathogenic, are downgraded to a VUS, or likely benign or benign, as larger datasets 712 
from expanded ethnicities become available.  713 
How to test. With the development of next generation sequencing (NGS), panels 714 
incorporating dozens of genes relevant to the phenotype have become the norm, as they are 715 
technically feasible and less costly.80 As a result, clinical genetic testing panels for these 716 
disorders are changing rapidly. Molecular genetic testing for multiple genes using a multi-gene 717 
panel is now the standard of practice for cardiovascular genetic medicine. Furthermore, multi-718 
gene panel genetic testing is recommended over a serial single-gene testing approach due to 719 
the genetically heterogeneous nature of cardiomyopathy. Genetic testing and cascade 720 
screening have been shown to be cost-effective.68, 69    721 
Large gene panels for cardiomyopathy may include genes that cause genetic syndromes 722 
associated with cardiomyopathy (eg. Fabry disease, Danon disease, Alström syndrome), 723 
neuromuscular conditions associated with cardiomyopathy (eg. limb girdle muscular 724 
dystrophies) or metabolic conditions. These large gene panels have the advantage of increasing 725 
the likelihood of identifying a molecular etiology, especially in patients with mixed phenotypes or 726 
those who lack pathognomonic features.86, 87 Considerable overlap of genes among different 727 
types of cardiomyopathy (and other phenotypes) is also well established (Supplemental Figure 728 
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1). Panels also increase the likelihood of identifying individuals who carry disease-causing 729 
variants in multiple genes, and this knowledge is extremely important for appropriate targeted 730 
testing of family members.  731 
With larger gene panels, the likelihood of identifying a VUS increases in proportion to the 732 
number of genes tested, increasing the complexity of the interpretation and genetic counseling. 733 
Importantly, the strength of evidence for gene-disease pairs on current panels differs, with some 734 
well-established genes having a wealth of information regarding disease-causing variants, while 735 
more recently identified genes having much less information available. The latter case increases 736 
the likelihood of a variant being classified as a VUS. The composition of gene panels varies by 737 
testing lab. It is critical that the ordering physician has an understanding of the uses, benefits, 738 
and limitations of specific test types in order to select the most appropriate test for their patient 739 
(Table 4.1). Addition of TTN and BAG3 to DCM panels increased genetic testing yield by more 740 
than 10%,15, 82, 83 but for HCM, recent studies have shown that expanded panels do not currently 741 
increase sensitivity.69 Thus the decision to order a panel that includes a larger number of genes 742 
should be based on the specifics of the patient’s medical history, physical exam findings, and 743 
family history.744 
HCM. The level of evidence for testing in HCM is based on studies showing a high 745 
diagnostic yield of genetic testing in children and adults and prognostic value of genotype 746 
status.30, 69, 72, 73, 88 HCM is considered a disease of the sarcomere, and variations in genes 747 
encoding sarcomeric proteins, in which there is low tolerance for genetic variation, are common 748 
causes.89 The diagnostic yield of HCM testing is approximately 30-60% (Table 4.2). The yield of 749 
testing is higher in individuals who have a known family history of HCM.69, 88 Pathogenic variants 750 
in MYH7 and MYBPC3 account for approximately 80% of all cases for which a molecular 751 
diagnosis is achieved.90, 91 Beyond sarcomeric genes, core genes to screen in patients with 752 
HCM include GLA, PRKAG2, and LAMP2, as reviewed in the Background of Guideline 3.  753 
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Infants and children with HCM may require more specialized evaluation and diagnostic 754 
testing as noted in Section 3 because of the rate of syndromic conditions and inborn errors of 755 
metabolism associated with HCM at these ages.49, 50, 92 Consultation with a geneticist is 756 
indicated.  757 
DCM. Evidence indicates that clinical genetic testing can identify the cause of DCM in758 
families with autosomal dominant inheritance in approximately 25-40% of cases, whereas in 759 
isolated cases of DCM, the yield of testing is commonly estimated at 10-25%.35, 93-95 Core genes 760 
to be tested in individuals with DCM include genes encoding sarcomeric and cytoskeletal 761 
proteins (Table 3), although DCM testing panels typically carry several dozen genes, some with 762 
uncertain significance. In most cases, all HCM and ARVC genes are included in DCM panels 763 
because of gene/phenotype overlap.  764 
Protein-truncating variants in TTN (TTNtv) represent the most common genetic testing 765 
finding in DCM, ranging from 10-20% of cases.15, 82, 83 While many commercial testing 766 
laboratories will adjudicate all TTNtv’s, whether singleton or familial, as pathogenic or likely 767 
pathogenic, variant interpretation is challenging due to the large size of the gene and the 768 
frequency of truncating TTN variants in reference populations.82, 83, 96, 97 Most studies have not 769 
been family-based, where segregation could be evaluated, but some non-segregation of 770 
TTNtv’s has been identified.98  Further, recent cardiac magnetic resonance data of normal 771 
individuals from a population-based study showed a small but significant decrement in LV 772 
function with TTNtv’s in constitutive cardiac exons,97 suggesting that in some cases a TTNtv 773 
may function as a risk allele.   774 
The LMNA gene is the second most commonly identified cause of DCM with a 775 
diagnostic yield of 5.5%, and gene-specific management recommendations, reviewed below, 776 
are available.99, 100 More recently identified genetic causes of DCM such as BAG3, a chaperone 777 
regulator, and RBM20, a protein required for RNA splicing, identify novel molecular mechanisms 778 
for disease101, 102, and are each identified in approximately 2% of DCM cases. DCM is a 779 
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common complication of neuromuscular disease such as Duchenne or Becker muscular 780 
dystrophy. Genetic testing is important in mothers of individuals with Duchenne or Becker to 781 
determine carrier status because carrier females may develop DCM in the third to fifth decade 782 
of life.103 As in HCM, infants and children with DCM may require additional diagnostic genetic 783 
evaluation.  784 
ARVC. The genetic basis of ARVC was initially identified as a disease of the 785 
desmosome.104 Genetic testing of PKP2, DSP, DSG2, DSC2, JUP, TMEM43, and PLN resulted 786 
in a molecular diagnosis in 63% of patients who fulfilled Task Force criteria for ARVC.105 Digenic 787 
inheritance and compound heterozygosity are frequent106 and, combined with decreased 788 
penetrance that is a feature of ARVC, may significantly complicate genetic counseling. ARVC 789 
overlaps with arrhythmogenic left ventricular cardiomyopathy, sometimes more broadly referred 790 
to as arrhythmogenic cardiomyopathy.107 This reflects genetic and phenotypic overlap among 791 
these forms of cardiomyopathy. Accordingly, genetic testing for ARVC using a larger 792 
cardiomyopathy panel may identify non-desmosomal genes with pathogenic variants. Similarly, 793 
desmosome gene mutations have also been identified in patients diagnosed with DCM.108 794 
Exercise has a well-established role in the pathogenesis of desmosomal cardiomyopathies, and 795 
recognition of a desmosome gene mutation can help to determine optimal exercise 796 
recommendations.109 797 
RCM. Genetic causes of RCM continue to be identified, but because RCM is a relatively 798 
rare form of cardiomyopathy, numbers remain limited. A recent study identified a pathogenic 799 
variant in 60% of subjects, primarily occurring in genes known to cause HCM.110 Family 800 
members were frequently identified with HCM or HCM with restrictive physiology. Cardiac 801 
amyloidosis resulting from pathogenic variants in TTR needs to be differentiated from other 802 
forms of RCM due to the age demographic in which this occurs, the slowly progressive nature of 803 
this disease, and therefore different management strategies.111, 112 The TTR allele  p.Val142Ile 804 
(commonly referred to as Val122Ile based on nomenclature for the circulating protein after N-805 
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terminal peptide cleavage) has been found in 10% of African Americans older than age 65 with 806 
severe congestive heart failure.113 Substantial recent progress with amyloidosis, both in imaging 807 
strategies, including cardiac magnetic resonance and pyrophosphate scanning, and therapeutic 808 
interventions in ongoing clinical trials, provide new incentives for genetic diagnosis.114 809 
Hemochromatosis is uncommon but easily excluded with iron studies, such as percent 810 
saturation of transferrin, and if present can be treated with iron removal.115  811 
LVNC. As noted above, the LVNC phenotype may be observed in conjunction with all 812 
other cardiomyopathy phenotypes, so considerations related to genetic testing should always be 813 
directed by findings of a cardiomyopathy (or other cardiovascular) phenotype.16, 116 Genetic 814 
testing is not recommended when the LVNC phenotype is identified serendipitously in 815 
asymptomatic individuals with otherwise normal cardiovascular structure and function.117  816 
Special Circumstances: A genetic etiology should be considered and a genetic 817 
evaluation conducted in cases of peripartum cardiomyopathy, as rare variants in genes known 818 
to cause DCM have been identified in patients with peripartum cardiomyopathy,118-120 and TTN 819 
truncating variants are present at rates similar to those found in the DCM population.120 In cases 820 
of sudden death with an autopsy diagnosis of cardiomyopathy, genetic testing may facilitate risk 821 
stratification of family members.121, 122      822 
823 
Interpretation of genetic testing. 824 
Genetic testing results are probabilistic rather that determinative, and thus rely on 825 
strength of evidence, both for and against, of specific variants causing or contributing to 826 
disease.  New guidelines have attempted to standardize and increase the stringency of 827 
interpretation, with greater clarity regarding the criteria for strength of evidence and the 828 
weighting of multiple sources of information that need to be incorporated to arrive at the 829 
interpretation.9 Despite this, the interpretations provided for a given variant may differ between 830 
clinical genetic testing laboratories.123, 124 In addition, updates and revisions of the laboratory 831 
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interpretation may occur as more information is obtained from larger cohorts, sometimes leading 832 
to re-issuing of a clinical report with changed interpretation by diagnostic laboratories. 833 
Because of their probabilistic nature, results of genetic testing must always be 834 
interpreted in the context of the patient’s medical and family history.85 For example, family 835 
history information and the segregation of a putative disease-causing variant within the family 836 
may be important information to guide clinical interpretation, especially in cases where novel 837 
genetic variants are identified. Also, family studies have noted more than one pathogenic variant 838 
in up to 10% of families with ARVC.125 Two or more variants have been seen in 3-5% of HCM 839 
cases,31-33 particularly if onset is early or severe.30 Although not reported systematically, digenic 840 
inheritance has been suggested to occur at even higher frequency with DCM.35  841 
The diagnostic yield of genetic testing for each subtype of cardiomyopathy is much less 842 
than 100% (Table 2) and a negative genetic test result (in this setting including VUS and likely 843 
benign or benign variants) does not rule out a genetic cause. Such an uninformative result in a 844 
proband simply indicates that the genetic testing performed was unable to identify the specific 845 
cause of disease in the given family. In these circumstances, an uninformative genetic testing 846 
result cannot be used for predictive, cascade genetic testing in unaffected relatives. Rather, 847 
family screening using phenotypic evaluations is recommended (Guideline 2). Larger panels, 848 
better coverage of the relevant genes, analysis for deletions, duplications, and rearrangements 849 
in the genes of interest, or exome sequencing in families with multiple living affected individuals 850 
may identify a genetic etiology.  851 
Finally, the recent availability of and much greater focus on extensive genetic testing 852 
panels should not diminish or distract from the critical importance of expert phenotyping of 853 
patients and families, and the relevance of highly insightful phenotype and gene-variant 854 
correlations. Current genetics practice suggests that results provided by molecular genetics 855 
laboratories drive clinical decision making, specifically actionability, in a genetic evaluation. In 856 
the Family Management section below, this guidance states that a VUS cannot be used for 857 
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predictive testing, which the writing group firmly supports. However, we acknowledge that 858 
compelling clinical data, for example, the pre-genetic test specification of a disease gene highly 859 
likely to harbor a disease-associated variant of interest, seldom impacts the clinician’s decision860 
of whether a variant classified as a VUS by a laboratory report is actionable. More specifically, 861 
cardiovascular genetics experts have become quite sanguine, for example, at specifying the 862 
pretest likelihood of identifying a LMNA variant based upon phenotype and/or family data. 863 
However, finding a novel missense or nonsense variant in any gene, even with such a pretest 864 
specification, cannot be classified with current ACMG rules as likely pathogenic (or pathogenic), 865 
and thus actionable, unless data regarding the same variant is available from multiple probands 866 
and/or affected family members. While we propose no solution to this present conundrum, we 867 
do acknowledge its existence. Efforts to accumulate extensive catalogs of expertly adjudicated 868 
phenotype and variant information, such as the ClinGen effort,10 may eventually partially 869 
mitigate this situation. 870 
871 
Considerations of Family Management 872 
Predictive Genetic Testing 873 
Risk stratification in family members is an important and valuable reason for genetic 874 
testing. If a pathogenic or likely pathogenic variant is identified in the index patient initially 875 
tested, opportunities emerge for the predictive testing of at-risk family members. As noted 876 
above, variants of uncertain significance (VUS) are not useful to conduct predictive genetic 877 
testing. 878 
Negative cascade genetic testing in an at-risk family member. If genetic testing is 879 
negative in an at-risk phenotype-negative family member for a pathogenic or likely pathogenic 880 
variant present in the proband, that family member’s risk of developing the cardiomyopathy is881 
substantially reduced. In this situation the need for serial phenotype screening after a baseline 882 
clinical evaluation in such a genotype-negative family member in most cases is unnecessary, 883 
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and the family member can be discharged from serial clinical phenotype screening. However, 884 
the strength of the recommendation to release a family member from ongoing interval 885 
phenotype screening is based upon the strength of the evidence that the variant indeed is the 886 
cause of disease in the family under care. In most cases this evidence must be assembled from 887 
prior patients and families, usually in publicly accessible databases or the medical literature, 888 
and/or from evidence gathered and assessed from the family under care. The family member 889 
should be counseled that their risk has been substantially reduced, but is not reduced to zero, 890 
with the caveat that if they develop relevant symptoms, phenotype screening should be 891 
reconsidered because of the possibility that one or more yet undetected variants may be at play. 892 
Positive cascade genetic testing in an at-risk family member. On the other hand, if a 893 
pathogenic or likely pathogenic variant is identified in an asymptomatic, at-risk phenotype-894 
negative family member, the confidence is much greater to infer risk for that individual. They 895 
should be counseled on the presenting signs and symptoms of the specific cardiomyopathy, any 896 
associated reduced penetrance and variable expressivity, and the rationale and frequency of 897 
the recommended clinical surveillance (reviewed at Guideline 2). 898 
899 
Leveraging Family-based Segregation Information to Impact Variant Analysis900 
Some variants detected with cardiomyopathy genetic testing will be novel, that is, 901 
variants that have not been previously reported in publicly accessible databases, and will meet 902 
other usual criteria for pathogenicity. However, even if the variant is of the type that is known to 903 
be disease-causing and has occurred in a well-established gene associated with the 904 
cardiomyopathy phenotype in the family, such novel variants will often be adjudicated as VUSs 905 
because of lack of prior case or family data. In this circumstance, searching for segregation of 906 
the variant in question with the cardiomyopathy phenotype in additional family members can 907 
provide additional valuable information. Depending upon the size of the pedigree, the number of 908 
individuals tested, and the genetic testing results, such information may help reclassify a variant 909 
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from VUS to pathogenic or benign. The ClinGen initiative10 proposes to rectify this issue by 910 
aggregating all available disease-associated variants into ClinVar, a publicly accessible 911 
database utilizing a standardized curation approach tailored after the ACMG/AMP 912 
recommendations,9 and all professionals with any access to genetic data relevant to the 913 
cardiomyopathies are urged to contribute to this important database. However, because of the 914 
numbers of genes involved in the cardiomyopathies, many variants in the near term will likely be 915 
curated as VUS’s. For example, in one HCM study, the cardiomyopathy with the largest 916 
disease-specific databases and where ~80% of pathogenic variants can be identified in two 917 
genes, MYPBC3 or MYH7, in one recent study 30% and 35% of variants were novel, 918 
respectively, for these two genes. In other well established HCM genes 76% of variants were 919 
unique.38  920 
The corollary of the above is that if the VUS does not segregate with affected family 921 
members, the likelihood that the VUS is relevant for the family phenotype is reduced. However, 922 
this analysis must encompass the growing reality of bilineal or multi-variant disease, which has 923 
been postulated to be more common in DCM8, 35 and ARVC.126  924 
In most clinical situations, sequencing a VUS is not undertaken in family members who 925 
have completed clinical screening and have been shown to be free of the phenotype (negative 926 
clinical phenotype screening), as genetic information will not inform variant pathogenicity. One 927 
important exception to this is parental sequencing to confirm the possibility of de novo 928 
occurrence of a variant. A second exception to this includes sequencing older unaffected family 929 
members, who are highly informative when assessing the penetrance of a variant. Application of 930 
this principle depends greatly upon the age of onset of the phenotype in the family (infant, 931 
pediatric, early adult, late adult), the clarity and severity of the phenotype, as well as the gene 932 
involved and disease mechanisms.  933 
Finally, as noted above, variant calls may change. The most problematic is when a previously 934 
called variant, deemed pathogenic or likely pathogenic, is downgraded to a VUS. In this circumstance, 935 
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recommendations for the clinical surveillance screening of at-risk family members change. Most 936 
importantly, a genotype-negative family member must now be counseled that they remain at risk for 937 
the family phenotype, and hence need to re-engage in clinical screening. The proband and any family 938 
members who tested positive for the variant, now downgraded to a VUS, must also be counseled that 939 
future genetic re-evaluation may be appropriate. All clinicians participating in genetic evaluations must 940 
be aware of the implications of changes in variant calls, and the family members should be counseled 941 
regarding these possibilities during the initial genetic evaluation and the need for possible future 942 
contact. Given the seeming recent increase in downgrading to a VUS, this highly impactful change in 943 
variant status carries great potential for unintended clinical errors if not identified and communicated 944 
effectively to the relevant family unit. 945 
946 
Guideline 5. Genetic counseling is recommended for all patients with 947 
cardiomyopathy and their family members. (Level of Evidence A) 948 
949 
Key Point: Genetic counseling for cardiomyopathy may be offered by board-certified or board-950 
eligible genetic counselors, clinical geneticists, or in the absence of available genetics 951 
professionals, by clinicians who have the required background, expertise and training. Genetic 952 
counseling for cardiomyopathy includes review of medical records essential for phenotyping, 953 
obtaining a pedigree, patient and family education, evaluating genetic testing options, obtaining 954 
consent for genetic testing, facilitating family communication, and ordering and interpreting 955 
genetic test results while addressing psychosocial issues.  956 
957 
Guideline 5 - Background958 
Genetic counseling facilitates understanding and adaptation to the impact of a genetic 959 
condition at the medical, psychological, and the family level,127 and is valued positively as an 960 
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essential service by both caregivers and patients.1, 46, 128 This service may be provided by 961 
clinical geneticists, genetic counselors, or specially trained nurses. In the United States this is 962 
performed mostly by genetic counselors, who are mid-level providers with a Masters level 963 
training in gathering, interpreting, and communicating medical genetics information. Their scope 964 
of practice also includes psychosocial assessment and support. Genetic counseling 965 
conceptualizes the family as the unit of care, with a broadened focus including preventive care 966 
for at-risk family members. 967 
Genetic counseling is usually undertaken by genetic counselors and/or clinical 968 
geneticists who are knowledgeable of the cardiovascular features of the type of cardiomyopathy 969 
in question, or by cardiologists, adult or pediatric, who are expert in the cardiomyopathy in 970 
question and are fluent in the content and nature of genetic counseling. Cardiologists with 971 
special interest and expertise in genetic cardiomyopathies usually integrate genetic counselors 972 
into their practice. 973 
Genetic counseling is an essential component of the evaluation, diagnosis, and 974 
management of the cardiomyopathies. Genetic counseling roles include review and gathering of 975 
medical records essential for phenotyping, obtaining a family history (Guideline 1), educating 976 
the patient and family regarding the disease transmission and family risks, evaluating genetic 977 
testing options (Guideline 4), obtaining consent for genetic testing including discussing the 978 
implications of positive, negative, or uncertain results, providing key information to other at-risk 979 
family members as identified by the index patient, ordering testing, interpreting genetic test 980 
results, as well as communicating results and their clinical implications, including screening 981 
recommendations for family members (Guideline 2). 982 
Counseling is also aimed to promote informed choices and adaptation to risk or 983 
condition while exploring and addressing psychosocial issues, as they emerge. Addressing 984 
family dynamics, which could potentially impact dissemination of genetic information to at-risk 985 
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family members, is an active area of focus in genetic counseling that may be aided by the use of 986 
patient letters, educational materials, or other communication tools. 987 
988 
Guideline 6. Focused cardiovascular phenotyping is recommended when 989 
pathogenic or likely pathogenic variants in cardiomyopathy genes, designated for 990 
reporting of secondary findings by the ACMG, are identified in an individual. 991 
992 
a. If a cardiovascular phenotype is identified as would be predicted by currently993 
available knowledge of the gene/variant pair, all usual approaches described in994 
this document for a genetic evaluation, including family-based approaches, are995 
recommended.996 
997 
b. If no cardiovascular disease phenotype is identified in the individual,998 
recommendations for surveillance screening at intervals should be considered.999 
1000 
c. If no cardiovascular phenotype is identified in the individual, cascade evaluation1001 
of at-risk relatives may be considered, tempered by the strength of evidence1002 
supporting the pathogenicity of the variant, the usual age of onset of the1003 
gene/variant pair, and pedigree information (e.g., the ages of at-risk family1004 
members, other previously known cardiovascular clinical data in the pedigree,1005 
and related information).1006 
1007 
Guideline 6 - Background1008 
Across specialties genetic testing is moving towards use of large gene panels, whole 1009 
exome sequencing, and potentially whole genome sequencing. These tests may be performed 1010 
for a wide variety of indications and diseases that do not include a cardiac phenotype. 1011 
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Individuals who undergo genetic testing for a disease that does not involve the heart may have 1012 
a genetic variant discovered that may predispose that individual to a cardiomyopathy. This 1013 
discovery may occur in two ways: 1) the gene, known to confer risk from high penetrance 1014 
variants that are medically actionable, may be intentionally analyzed as recommended by the 1015 
American College of Medical Genetics and Genomics. Variants identified from intentional 1016 
analysis are termed secondary findings. 2) A variant is identified incidentally or accidentally 1017 
through the analysis of genes related to the original phenotype for which the test was 1018 
performed. These are termed incidental findings. 1019 
The ACMG has developed guidelines to manage secondary findings, which were first 1020 
published in 20134 and updated in 2016.5 The ACMG guidance directs the reporting only of 1021 
Known Pathogenic (KP) or Expected Pathogenic (EP) variants,5 the former defined as 1022 
“Sequence variation is previously reported and is a recognized cause of the disorder” and the1023 
latter as “Sequence variation is previously unreported and is of the type which is expected to 1024 
cause the disorder.” These definitions were taken from the ACMG 2008 guidance for variant 1025 
interpretation,129 which was updated by the ACMG/AMP in 20159 with modified nomenclature of 1026 
“pathogenic” (P) and “likely pathogenic” (LP). The latter attributions (P, LP) are now nearly 1027 
universally used in clinical genetic testing laboratories in the US. This nomenclature is also used 1028 
in ClinGen10, 11, the ClinGen Cardiovascular Clinical Domain Working Group,130 and this 1029 
guideline. Despite possible subtle differences of KP/EP and P/LP, since the P and LP 1030 
attributions are used for the other specific numbered guidelines in this document, for simplicity 1031 
and parsimony these attributions will also be used in this section. 1032 
Thus, variants in the ACMG-listed cardiomyopathy genes (Table 3) that have been 1033 
identified as secondary findings and adjudicated as P or LP are considered medically 1034 
actionable. In those cases, cardiac phenotyping should be conducted in the individuals who 1035 
carry those variants, assuming that the individual has not opted out of notification.  1036 
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Greater difficulty in determining whether a variant is medically actionable may occur for 1037 
incidental findings reported by the diagnostic laboratory that fall outside the ACMG guidelines. 1038 
Incidental findings may be classified as pathogenic, likely pathogenic, variants of uncertain 1039 
significance, likely benign or benign, with specific criteria for the strength of assertion.9  1040 
The single most important analysis for determining if a specific incidental finding is 1041 
actionable rests on the strength of evidence for disease causality of the gene/variant pair. 1042 
Identifying a variant in a gene previously observed in multiple cases or families, including at 1043 
times functional data confirming a damaging effect, can have substantial evidentiary strength, 1044 
and such variants may be able to be classified as pathogenic or likely pathogenic. Such 1045 
evidence forms the basis of the ACMG recommendations and informs sections a, b, and c of 1046 
this guideline. For HCM, where 80% of genetic cause, when found, is within two genes 1047 
(MYBPC3, MYH7), a greater likelihood exists that prior case data may be available. However, in 1048 
contrast to HCM, the gene ontology for DCM is much more extensive, as most genes contribute 1049 
only a small fraction to the totality of known genetic cause, and many reported variants remain 1050 
private. The number of genes considered relevant for ARVC is smaller than either DCM or 1051 
HCM, but because it is much less common than HCM or DCM, many ARVC variants will also 1052 
remain private. Overall it is likely that most cardiomyopathy variants identified as incidental 1053 
findings, even those for HCM, will remain VUSs because of lack of prior data, or lack of the 1054 
requisite genetic data to assess segregation in large and well phenotyped families with multiple 1055 
affected individuals.  1056 
Item C of this guideline suggests thoughtful and cautiously implemented, cascade 1057 
clinical (phenotype) screening of putatively at-risk family members may be considered, even if 1058 
the clinical phenotype screening was negative in the individual (proband) who completed 1059 
genetic analysis. This statement recognizes the possibility that the proband may be younger 1060 
than the usual age of onset of the cardiovascular phenotype. It also recognizes the utility and 1061 
necessity of gathering clinical phenotype data in an extended family to help interpret the genetic 1062 
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information in cascade testing if phenotypes are encountered in the family members predicted 1063 
by the gene/variant pair.  1064 
We also recognize that at times a novel variant will be identified in an established, well-1065 
curated131 gene known to have other variants of high risk, and the variant will be recognized as 1066 
the type that is expected to be pathogenic, but because it is novel it may be appropriately 1067 
adjudicated as a VUS. In select situations within the context of expert evaluation described 1068 
above (Guideline 3) and known limitations summing the integrated risk derived from molecular 1069 
genetics and clinical knowledge of the gene/variant pair (Guideline 4), a personal and family 1070 
history, pedigree analysis and phenotyping of the individual harboring such a VUS may be 1071 
considered. The rationale for this comment results directly from the significant risk of morbidity 1072 
and mortality noted above that may devolve from such cardiomyopathy genes and variants. If 1073 
phenotype evidence is found to support a disease association in the individual, the remainder of 1074 
these guidelines would become operative, including consideration of pedigree expansion to help 1075 
establish or refute the pathogenicity of the variant, and to better discern the overall risk incurred 1076 
to the individual and the family.  1077 
A distinct limitation is that we are unaware of published outcomes data to support, 1078 
validate, or refute the above guidance, which can only be considered as expert opinion. This 1079 
emphasizes the need for well-designed rigorous studies examining outcomes of phenotyping 1080 
and family studies following secondary or incidental findings of variants relevant for the 1081 
cardiomyopathies.  1082 
1083 
Therapy Based on Genetic Evaluation and Cardiac Phenotype 1084 
The clinical characteristics associated with variants in some disease genes, when 1085 
integrated with pedigree data, may directly influence the overall assessment and clinical 1086 
recommendations for a patient or family.  1087 
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One gene with substantial evidence fitting this situation is LMNA, which commonly 1088 
presents with nonsyndromic cardiomyopathy in adult cardiology practice and is well known for 1089 
progressive conduction system disease (first-, second-, or third-degree heart block), usually with 1090 
supraventricular and/or ventricular arrhythmias prior to, during or soon thereafter. All of this may 1091 
occur prior to or contemporaneously with early DCM. Because in the US the use of ICDs is not 1092 
recommended until the left ventricular ejection fraction (LVEF) falls to less than 35%, patients 1093 
with LMNA cardiomyopathy may have inadequate protection from life-threatening ventricular 1094 
arrhythmias if the LVEF remains >35%.78, 132 For this reason a specific guideline was created for 1095 
the 2009 HFSA guideline1  and has been preserved (Guideline 9). Other DCM genes (e.g., DES 1096 
or SCN5A, FLNC and other genes not yet identified) may also have prominent risk of lethal 1097 
arrhythmia and may also benefit from earlier ICD use.133 As noted above, arrhythmia or sudden 1098 
cardiac death, may precede the development of cardiomyopathy, and may be the presenting 1099 
feature. 1100 
Other genes with mutations causing syndromic diseases involving cardiomyopathy that 1101 
have clear therapeutic indications include GLA, which encodes alpha-galactosidase A, and 1102 
GAA, encoding alpha-glucosidase. Deficiencies of these enzymes cause Fabry or Pompe 1103 
disease, respectively. Both have protein replacement treatments that have been shown to be 1104 
efficacious.134, 1351105 
The rationale for conducting genetic evaluations for the cardiomyopathies rests on the 1106 
concept that in most cases treatment interventions once clinical disease has been recognized 1107 
can forestall progressive disease and/or anticipate and prevent complications of disease 1108 
progression. Each cardiomyopathy type has its own considerations that exceed the scope of 1109 
this genetics oriented document. However, even surveillance for common complications (e.g., 1110 
sudden cardiac death, either from brady- or tachy arrhythmias in progressive LMNA 1111 
cardiomyopathy; atrial fibrillation in long standing HCM; onset of heart failure in previously 1112 
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asymptomatic but progressive DCM) can trigger appropriate interventions with drugs and/or 1113 
devices to prevent or ameliorate disease, as reviewed below. 1114 
The role and risks of exercise in cardiomyopathy, and questions regarding exercise 1115 
limitation, are frequently raised by patients and families. These have been addressed in other 1116 
guideline statements.136 1117 
1118 
7. Medical therapy based on cardiac phenotype is recommended as outlined in1119 
consensus guidelines. Level of Evidence = A. 1120 
Guidelines for the evaluation and management of patients with cardiomyopathy have 1121 
been published for HCM,137, 138 DCM,6, 139-141 and ARVC.142 These guidelines provide 1122 
comprehensive guidance for care of those who are presymptomatic (stage B heart failure) or 1123 
have had the onset of symptoms (stage C or D heart failure). Guidelines for the clinical care of 1124 
patients with RCM are not yet available. Controversy continues whether LVNC represents an 1125 
anatomical phenotype or distinct cardiomyopathy, and even when observed no specific 1126 
treatment is indicated other than for associated cardiovascular phenotypes, as reviewed above. 1127 
A multi-society (ACC/AHA/HFSA) guideline update for management of patients with heart failure 1128 
has recently been published.140 1129 
1130 
8. Device therapies for arrhythmia and conduction system disease based on1131 
cardiac phenotype are recommended as outlined in consensus guidelines. Level 1132 
of Evidence = B. 1133 
In brief, ICDs are indicated for secondary prevention of ventricular tachycardia or 1134 
ventricular fibrillation regardless of the type of cardiomyopathy or degree of ventricular 1135 
dysfunction. The indications for ICDs for primary prevention of sudden cardiac death in patients 1136 
with nonischemic cardiomyopathy with reduced ejection fraction of any etiology are summarized 1137 
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in guideline statements,6, 139, 143-145 even though some ICD trials excluded individuals with familial 1138 
cardiomyopathy associated with sudden death.146 Device therapy for arrhythmia should not rely 1139 
exclusively on the presence of a P or LP gene variant but must be integrated into overall 1140 
attributable risk. For DCM, ICD therapy is indicated in patients who have a left ventricular 1141 
ejection fraction less than or equal to 35% and who are in NYHA functional Class II or III (class 1142 
I, level of evidence B).  Additional class II and III guideline recommendations144 are provided in 1143 
Supplementary Table 3. 1144 
1145 
9. In patients with cardiomyopathy and significant arrhythmia or known risk of1146 
arrhythmia an ICD may be considered before the left ventricular ejection fraction 1147 
falls below 35%. Level of Evidence = C. 1148 
Electrophysiological disease can be considered broadly as conduction system disease 1149 
and arrhythmia. Please see the discussion above regarding LMNA cardiomyopathy, however 1150 
this guideline applies to any genetic cardiomyopathy that presents or progresses to lethal 1151 
arrhythmia or heart block prior to advanced LV dysfunction. Examples of other conditions 1152 
include the myotonic dystrophies.58 Conventional guidelines apply for symptomatic or pre-1153 
symptomatic conduction system disease regardless of other aspects of the patient’s clinical1154 
situation.144 Pacemakers are indicated for symptomatic bradycardia, high grade AV block 1155 
regardless of symptoms, or for any other symptomatic conduction system disease. Pacemakers 1156 
may also be considered to allow for the institution of disease-modifying therapy (e.g., beta-1157 
blockers) when limited by bradycardia or along with AV junction ablation to treat refractory atrial 1158 
fibrillation with rapid ventricular response. In the setting of LMNA cardiomyopathy and other 1159 
genetic conditions with similar risk profiles requiring pacemaker placement, the use of an ICD 1160 
rather than a pacemaker has been previously recommended1 and is supported by extensive 1161 
literature documenting the risks of sudden cardiac death concurrent with conduction system 1162 
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disease requiring pacemaker placement.76, 78, 99, 100, 147-150 For a patient with reduced ejection 1163 
fraction that is likely to require chronic ventricular pacing, placement of a cardiac 1164 
resynchronization therapy device (e.g., CRT-D) should be considered. 1165 
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Table 1. Studies Recommended in Baseline Clinical Phenotyping. 
Study DCM HCM ARVC LVNC RCM 
CK-MM1 X X 
ECG X X X X X 
ETT2 X X3 
Holter monitoring X X X 
CMR4 X X X X X 
Metabolic dis-
ease screening5 
X X X X 
1CK-MM is the MM band (skeletal muscle) fraction of creatine kinase and should be completed if 
syndromic or neuromuscular disease is suspected. 2ETT, exercise treadmill testing. 3In children. 
4Cardiac magnetic resonance imaging (CMR) is recommended if echocardiography is 
insufficient to define the phenotype; this is relevant to assess the cardiac morphology and 
function for all of the cardiomyopathies, and the presence and degree of fibrosis inferred from 
gadolinium uptake. 5Additional screening tests are indicated for pediatric onset and select adult 
onset presentations, see Guideline 3.   
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Table 2. Suggested Clinical Phenotype Screening Intervals by Age and Cardiomyopathy for 
Unaffected First-Degree Family Members of Affected Individuals 
Cardiomyopathy 0-5 years2 6-12 years 13-19 years
20-50
years 
>50 years
DCM 
Annually with positive 
FDR1 
1-2 years with
positive FDR1 
1-3 years 2-3 years 5 years 
HCM 
Annually with positive 
FDR1 
1-2 years with
positive FDR1 
2-3 years 5 years 5 years 
ARVC 
Consider once with 
positive FDR1 
5 years 1-3 years 2-3 years 3 years 
RCM 
Annually with positive 
FDR1 
1-2 years with
positive FDR1 
2-3 years 3 years 5 years 
1Positive FDR means that the unaffected but at-risk family member has a first-degree relative with 
the phenotype of interest. These screening intervals apply to at-risk family members when genetic 
testing: has not been performed or is uninformative in the proband, or when it has identified a 
likely pathogenic or pathogenic variant in the at-risk family member.   
2Although most DCM is adult-onset and most HCM is adolescent- or adult-onset, both occur in neonates 
and young children. ARVC is early adult- to adult-onset. Data are limited for RCM.  
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Table 3. Selected Genes in Association with Cardiomyopathy 
Core genes1 
Estimates 
of genetic 
testing 
diagnostic 
yield 
ACMG 
Secondary 
Findings Gene 
List 
Metabolic 
Causes of 
Cardio-
myopathty 
Examples of 
Genetic 
Syndromes 
HCM MYH7, MYBPC3, TNNT2, 
TNNC1, TNNI3, TPM1, MYL2, 
MYL3, ACTC1, ACTN2, CSRP3, 
PLN, TTR, PRKAG2, LAMP2, 
GLA 
30-60% MYBPC3, 
MYH7, TNNT2, 
TNNI3, TPM1, 
MYL3, ACTC1, 
PRKAG2, GLA, 
MYL2, LMNA 
GAA 
(Pompe); 
Mitochondrial 
disease genes 
RASopathies 
(e.g., Noonan 
syndrome, 
others); 
Friedreich ataxia 
DCM TTN2, LMNA, MYH7, TNNT2,
BAG3, RBM20, TNNC1, TNNI3, 
TPM1, SCN5A, PLN. For testing, 
all HCM, ARVC genes are 
recommended to be included. 
10-40% Mitochondrial 
disease genes 
Muscular 
dystrophies; 
Alström 
syndrome 
ARVC DES, DSC2, DSG2, DSP, JUP, 
LMNA, PKP2, PLN, RYR2, 
SCN5A, TMEM43, TTN
2; 
consider full DCM panel 
10-50% PKP2, DSP, 
DSC2, 
TMEM43, 
DSG2, RYR2 
SCN5A 
Naxos 
syndrome; 
Carvajal 
syndrome 
RCM Consider HCM or DCM gene 
panel 
10-60%
LVNC Use the gene panel for the 
cardiomyopathy identified in 
association with the LVNC 
phenotype 
Unknown Mitochondrial 
disease genes 
including TAZ 
in Barth 
syndrome 
1p36 deletion 
syndrome; 
RASopathies 
1Core gene lists represent genes with the highest diagnostic yield and/or strongest evidence of the gene in 
association with the listed phenotype; the genes listed are not exhaustive and should be considered illustrative for the 
type of cardiomyopathy. Considerable overlap of genes between cardiomyopathy phenotypes is well established. 
Genes known to cause metabolic disease or genetic syndromes are often included in testing panels, but vary 
depending on the clinical laboratory. Gene lists therefore need to be reviewed carefully before ordering testing. 
Metabolic and genetic syndrome columns provide examples only and are not intended to be comprehensive. 2Only 
TTN truncating variants are thought relevant for cardiomyopathy.  
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